Background: Psoriasis is a chronic recurrent inflammatory skin disease with a high risk of diabetes based on disease severity. Objectives: The aim of the study was to evaluate the efficacy of different hypoglycemic medications in patients with psoriasis. Methods: A systematic review and meta-analysis of studies were conducted to evaluate the efficacy of hypoglycemic medications in patients with psoriasis. The primary outcome was of changes in the psoriasis area and severity index (PASI) score, and a 75% improvement in PASI from baseline (PASI75). Subgroup analysis was used to investigate associations among the types of hypoglycemic medicines, combination therapy, patient characteristics, course of treatment, and curative effect. Results: We included 3,286 patients from 19 studies to explore the effects of hypoglycemic medications. Patients randomized to receive hypoglycemic medicines showed a more significant decrease in the PASI score (standard mean difference = −0.55, 95% confidence interval (CI): −0.87 to −0.23, p = 0.0007) and a higher PASI75 ratio (RR: 1.80, 95% CI: 1.20–2.71, p = 0.0046). Patients consuming thiazolidinediones (TZDs) were more likely to reach PASI75 than those consuming glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase 4 inhibitors. The combined use of hypoglycemic medicines had an add-on effect on the standard psoriasis treatment, and the proportion of PASI75 in the combination group was nearly four times that in the noncombination group (p = 0.0216). In addition, hypoglycemic medications can reduce body weight, waist circumference, triglyceride, total cholesterol, low-density lipoprotein, and systolic blood pressure. Conclusions: Certain hypoglycemic drugs, such as GLP-1 RAs and TZDs, are beneficial for treating psoriasis. Multidisciplinary collaboration is recommended for the management of systemic inflammation in patients with psoriasis and diabetes.

Keywords:
Hypoglycemic medicines, Psoriasis, Glucose metabolism, Lipid metabolism, Cardiovascular disease
1.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.
2.
World Health Organization. Global report on psoriasis: world health organization. 2016. (accessed February 13, 2020).
3.
Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;8:743180.
4.
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
5.
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for themanagement and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
6.
Vázquez López F, González-Lara L, Martin JS, Argenziano G. Dr. K. Holubar (1936–2013). Teaching with dermoscopy: revealing the subsurface morphology of Auspitz’s sign and psoriasis. Int J Dermatol. 2014;53(5):e322–4.
7.
Armstrong AW, Read C. Pathophysiology. Clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.
8.
GBD 2019 Diabetes Mortality Collaborators. Diabetes mortality and trends before 25 years of age: an analysis of the global burden of disease study 2019. Lancet Diabetes Endocrinol. 2022;10(3):177–92.
9.
Vijan S. The clinic. Type 2 diabetes. Ann Intern Med. 2010;152:ITC31–15
10.
IDF International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels; 2017.
11.
Khalid U, Hansen PR, Gislason GH, Lindhardsen J, Kristensen SL, Winther SA, et al. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care. 2013;36(8):2402–7.
12.
Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke a population-based cohort study. Circulation. 2014;130(10):837–44.
13.
Psoriasis Professional Committee of Dermatology and venereology Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of psoriasis in China (2018 simplified edition). Chin J Dermatol. 2019;52(4):223–30.
14.
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
15.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
16.
Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract. 2019;150:167–73.
17.
Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients: a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29(3):555–9.
18.
Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, Van Belle A, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014;171(1):155–61.
19.
Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440–3.
20.
Lynch M, Malara A, Timoney I, Ahern T, Awdeh F, Sweeney C, et al. Dipeptidyl peptidase-4 inhibition in psoriasis patients with diabetes: a double-blind randomized controlled trial. Dermatology. 2021;237(1):66–9.
21.
Hadi N, Al-Dhalimi A, al Harchan N. Effect of sitagliptin on glycemic profiles and their correlation with pasi score in patients with plaque psoriasis. Am J Biomed. 2016;4(10):410–20.
22.
Lynch M, Ahern TB, Timoney I, Sweeney C, Kelly G, Hughes R, et al. Interim analysis of dipeptidyl peptidase-4 inhibition and narrowband ultraviolet B light in Psoriasis (DINUP): a randomized controlled trial. Br J Dermatol. 2015;173:65.
23.
Narang T, Dogra S, Handa S. Serendipity opens new avenues: a pilot study to evaluate the efficacy of saxagliptin in combination with cyclosporine and acitretin in diabetic psoriasis patients. Dermatol Ther. 2012;2:S36–7.
24.
Abidi A, Rizvi DA, Saxena K, Chaudhary S, Ahmad A. The evaluation of efficacy and safety of methotrexate and pioglitazone in psoriasis patients: a randomized, open-labeled, active-controlled clinical trial. Indian J Pharmacol. 2020;52(1):16–22.
25.
Ghiasi M, Ebrahimi S, Lajevardi V, Taraz M, Azizpour A. Efficacy and safety of pioglitazone plus phototherapy versus phototherapy in patients with plaque type psoriasis: a double blinded randomized controlled trial. J Dermatolog Treat. 2018;30(7):664–7.
26.
Hafez VG, Bosseila M, Abdel Halim MRE, Shaker OG, Kamal M, Kareem HS. Clinical effects of “pioglitazone,” an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. J Dermatolog Treat. 2015;26(3):208–14.
27.
Lajevardi V, Hallaji Z, Daklan S, Abedini R, Goodarzi A, Abdolreza M. The efficacy of methotrexate plus pioglitazone versus methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol. 2015;54(1):95–101.
28.
Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol. 2009;145(4):387–93.
29.
Ellis CN, Barker JN, Haig AE, Parker CA, Daly S, Jayawardene DA, et al. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol. 2007;8(2):93–102.
30.
Shafiq N, Malhotra S, Pandhi P, Gupta M, Kumar B, Sandhu K. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol. 2005;44(4):328–33.
31.
Pershadsingh HA, Sproul JA, Benjamin E, Finnegan J, Amin NM. Treatment of psoriasis with troglitazone therapy. Arch Dermatol. 1998;134(10):1304–5.
32.
Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol. 2016;16(1):12.
33.
El-Gharabawy RM, Ahmed AS, Al-Najjar AH. Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis. Biomed Pharmacother. 2017;85:141–7.
34.
Chi CC, Lee CY, Liu CY, Wang SH, Tien O’Donnell F, Tung TH. Effects of antidiabetic drugs on psoriasis: a meta-analysis. Eur J Clin Invest. 2021;51(2):e13377.
35.
Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301–7.
36.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–4.
37.
Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239–46.
38.
Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4):665–73.
39.
Grant PJ, Cosentino F, Aboyans V, Bailey CJ, Ceriello A, Delgado V. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;40(39):3215–7.
40.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021;46:101102.
41.
Novelli M, Savola P, Fierro MT, Vrrrone A, Quaglino P, Bernengo MG. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol. 1996;134:1052–6.
42.
van Lingen RG, van de Kerkhof PCM, Seyger MMB, de Jong EMGJ, van Rens DWA, Poll MKP, et al. CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol. 2008;158(6):1264–72.
43.
Raynaud F, Bauvois B, Gerbaud P, Evain-Brion D. Characterization of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology. J Cel Physiol. 1992;151(2):378–85.
44.
Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol. 2012;188(11):5438–47.
45.
Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor- gamma inhibit keratinocyte proliferation. Arch Dermatol. 2000;136(5):609–16.
46.
Bhagavathula N, Nerusu KC, Lal A, Ellis CN, Chittiboyina A, Avery MA, et al. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol. 2004;122(1):130–9.
47.
Venkatraman MS, Chittiboyina A, Meingassner J, Ho CI, Varani J, Ellis CN, et al. Alpha-lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases. Arch Dermatol Res. 2004;296(3):97–104.
48.
Giorgini AE, Beales PE, Mire-Sluis A, Scott D, Liddi R, Pozzilli P. Troglitazone exhibits immunomodulatory activity on the cytokine production of activated human lymphocytes. Horm Metab Res. 1999;31:1–4.
49.
Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–6.
50.
Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem. 2000;275(7):4541–4.
51.
Pacifico A, Conic RRZ, Cristaudo A, Garbarino S, Ardigò M, Morrone A, et al. Diet-related phototoxic reactions in psoriatic patients undergoing phototherapy: results from a multicenter prospective study. Nutrients. 2021;13(9):2934.
52.
Damiani G, Watad A, Bridgewood C, Pigatto PDM, Pacifico A, Malagoli P, et al. The impact of ramadan fasting on the reduction of PASI score, in moderate-to-severe psoriatic patients: a real-life multicenter study. Nutrients. 2019;11(2):277.
53.
Kocic H, Damiani G, Stamenkovic B, Tirant M, Jovic A, Tiodorovic D, et al. Dietary compounds as potential modulators of microRNA expression in psoriasis. Ther Adv Chronic Dis. 2019;10:2040622319864805.
54.
Damiani G, Allocco F; Young Dermatologists Italian Network, Malagoli P. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers. Clin Exp Dermatol. 2021;46(6):1106–8.
55.
Gisondi P, Piaserico S, Naldi L, Dapavo P, Conti A, Malagoli P, et al. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience. J Allergy Clin Immunol. 2021;147(2):558–60.e1.
56.
Bragazzi NL, Riccò M, Pacifico A, Malagoli P, Kridin K, Pigatto P, et al. COVID-19 knowledge prevents biologics discontinuation: data from an Italian multicenter survey during RED-ZONE declaration. Dermatol Ther. 2020;33(4):e13508.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.